Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1802-1808

  Michael, M ^a   Babic, B ^a   Khokha, R ^a   Tsao, M ^a   Ho, J ^a   Pintilie, M ^a   Leco, K ^a   Chamberlain, D ^a   Shepherd, F A ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COLLAGENASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VINCRISTINE;

ADULT; ARTICLE; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH;

EID: 0033047083     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1802     Document Type: Article

References (41)

1. Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336, 1991
2. Stetler-Stevenson W, Aznavovoorian S, Liotta LA: Tumour cell interactions with the extracellular matrix during invasion and metastasis. Cell Biol 9:541-573, 1993
3. Chambers AF, Matrisian LM: Changing views of the role of metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270, 1997
4. Denhardt DT, Feng B, Edwards DR, et al: Tissue inhibitor of metalloproteinases (TIMP, aka EPA): Structure, control of expression and biological functions. Pharmacol Ther 59:329-341, 1993
5. Himelstein BP, Canete-Soler R, Bernhard EJ, et al: Metalloproteinases in tumor progression: The contribution of MMP-9. Invasion Metastasis 14:246-258, 1994
6. Denhardt DT: On the paradoxical ability of TIMPs either to inhibit or to promote the development and progression of the malignant phenotype, in Hawkes SP, Edwards DR, Khokha R (eds): Inhibitors of Metalloproteinases in Development and Disease. Laussanne, Switzerland, Harwood Academic (in press)
7. Young TN, Rodriguez GC, Rinehart AR, et al: Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase-2. Gynecol Oncol 62:89-99, 1996
8. Tryggvason K, Hoyhtya M, Pyke C: Type IV collagenases in invasive tumors. Breast Cancer Res Treat 24:209-218, 1993
9. Davies B, Waxman J, Wasan H, et al: Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365-5369, 1993
10. Nakagawa H, Yagihashi S: Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung. Jpn J Cancer Res 85:934-938, 1994
11. Rouyer N, Wolf C, Chenard MP, et al: Stromelysin-3 gene expression in human cancer: An overview. Invasion Metastasis 14:269-275, 1994-95
12. Muller D, Wolf C, Abecassis J, et al: Increased stromelysin 3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinoma. Cancer Res 53:165-169, 1993
13. Garbisa S, Scagliotti G, Masiero L, et al: Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52:4548-4549, 1992
14. Kodate M, Kasai T, Hashimoto H, et al: Expression of matrix metalloproteinase (gelatinase) in T1 adenocarcinoma of the lung. Pathol Int 47:461-469, 1997
15. Hardy F, Fadlon E, Cottam D, et al: Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 69:177-182, 1994
16. Sier CFM, Kubben FJGM, Ganesh S, et al: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74:413-417, 1996
17. Zeng SZ, Huang Y, Cohen AM, et al: Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14:3133-3140, 1996
18. Ihde DC, Pass HI, Glatstein EJ: Small cell lung cancer, in De Vita V, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed4). Philadelphia, PA, Lippincott, 1993, pp 723-758
19. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15:62-75, 1997
20. Zucker S, Turpeeniemi-Hujanen T, Wieman JM, et al: Characterization of a connective tissue degrading metalloproteinase from human small cell lung cancer cells. Clin Exp Metastasis 6:363-375, 1988
21. Urbanski SJ, Edwards DR, Maitland A, et al: Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 66:1188-1194, 1992
22. Tokuraku M, Sato H, Murakami S, et al: Activation of precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase [MT-MMP] and with lymph node metastasis. Int J Cancer 64:355-359, 1995
23. Kawano N, Osawa H, Ito T, et al: Expression of gelatinase-A, tissue inhibitor of metalloproteinase-2, matrilysin, and trypsin(ogen) in lung neoplasms: An immunohistochemical study. Hum Pathol 28:613-622, 1997
24. Tsao M-S, Liu N, Nicklee T, et al: Angiogenesis correlates with vascular endothelial growth factor expression but not with ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res 3:1807-1814, 1997
25. Harvey MB, Leco KJ, Arcellana-Panlilio MY: Proteinase expression in early mouse embryos is regulated by leukemia inhibitory factor and epidermal growth factor. Development 121:1005-1014, 1995
26. de Wet M, Falkson G, Rapoport BL: Small cell lung cancer: Analysis of factors influencing the response to treatment and survival. Oncology 51:523-534, 1994
27. Kossakowska AE, Huchcroft SA, Urbanski SJ, et al: Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphoma in humans. Br J Cancer 73:1401-1408, 1996
28. Maurer LH, Pajak TF: Prognostic factors in small cell carcinoma of the lung: A Cancer and Leukemia Group B study. Cancer Treat Rep 65:767-774, 1981
29. Souhami RL, Bradbury I, Geddes D, et al: Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 45:2876-2882, 1985
30. Osterlind K, Andersen PK: Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 46:4189-4194, 1986
31. Ihde DC, Makuch RW, Carney DN et al: Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy. Am Rev Respir Dis 123:500-507, 1981
32. Wolf M, Holle R, Hans K, et al: Analysis of prognostic factors in 766 patients with small cell lung cancer: The role of sex as a predictor for survival. Br J Cancer 63:986-992, 1991
33. Boasberg P, Harbaugh B, Roth B, et al: Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 15:258a, 1996 (abstr)
34. Malfetano J, Teng N, Moore D, et al: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced cancer of the ovary: A dose finding study. Proc Am Soc Clin Oncol 15:283a, 1996 (abstr)
35. Rosemary A, Harris J, Langleben A, et al: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. Proc Am Soc Clin Oncol 15:207a, 1996 (abstr)
36. Pluda JM: Tumor-associated angiogenesis: Mechanisms, clinical implications and therapeutic strategies. Semin Oncol 24:203-218, 1997
37. Nawrocki B, Polette M, Marchand V, et al: Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: Quantitative and morphologic analyses. Int J Cancer 72:556-564, 1997
38. Zeng ZS, Cohen AM, Zhang ZF, et al: Elevated levels of tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1:899-906, 1995
39. Fong KM, Kida Y, Zimmerman PV, et al: TIMP 1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 2:1369-1372, 1996
40. Imai K, Ohuchi E, Aoki T, et al: Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinase 2. Cancer Res 56:2707-2710, 1996
41. Hayakawa T, Yamashita KM, Tanzawa K, et al: Growth-promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells: A possible new growth factor in serum. FEBS Lett 298:29-32, 1992